Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

By inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies ...

A medical expert discusses how Lambert-Eaton myasthenic syndrome is closely linked to small cell lung cancer, the challenges ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Merck's (MRK) antibody drug conjugate sac-TMT has received FDA Breakthrough Therapy designation for the treatment of EGFR-mutated lung cancer. Read more here.

The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed ...

This page includes links to articles highlighting the top lung cancer research published on Cancer Therapy Advisor in 2024.

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $87 from $82 and keeps a Buy rating on the ...